Reata Pharmaceuticals competitorsClear all
Reata Pharmaceuticals's top competitors include Aimmune Therapeutics, MyoKardia, Otonomy and Vertex Pharmaceuticals.
| Save Comparison |  Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. |  Aimmune Therapeutics Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. |  MyoKardia MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. |  Otonomy Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. |  Vertex Pharmaceuticals Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases. |
Founding Date | Founding Date 2002 | Founding Date 2011 | Founding Date 2012 | Founding Date 2008 | Founding Date 1989 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Plano, US HQ Irving, US Plano, US | Locations Brisbane, US HQ München, DE Dublin, IE London, GB Durham, US | Locations South San Francisco, US HQ Brisbane, US | Locations San Diego, US HQ | |
Employees | Employees 22079% increase | Employees 2755% increase | Employees 23542% increase | Employees 49 | Employees 3,00020% increase |
Valuation ($) | Valuation ($) 3.9 b | Valuation ($) 2.3 b | Valuation ($) 12 b | Valuation ($) 193.4 m | Valuation ($) 58.6 b |
Twitter followers | Twitter followers 1.1 k | Twitter followers 1.6 k | Twitter followers 1.2 k | Twitter followers 214 | Twitter followers 65.2 k |
Number of tweets (last 30 days) | Number of tweets (last 30 days) 14 | Number of tweets (last 30 days) 1 | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) N/A | Number of tweets (last 30 days) 5 |
Average likes per tweet (last 30 days) | Average likes per tweet (last 30 days) 4.6 | Average likes per tweet (last 30 days) 8 | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) N/A | Average likes per tweet (last 30 days) 30.2 |
Percentage of tweets with engagement (last 30 days) | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) 100% | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) N/A | Percentage of tweets with engagement (last 30 days) 100% |
Alexa Website Rank | Alexa Website Rank 283162 | Alexa Website Rank 193253 | Alexa Website Rank 239431 | Alexa Website Rank 339305 | Alexa Website Rank 145684 |
Employee Rating | Employee Rating 3.9 | Employee Rating 4.3 | Employee Rating 4.2 | Employee Rating 4.3 | Employee Rating 3.4 |
Financial | |||||
Revenue (est.) | Revenue (est.) $26.5m (FY, 2019) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $600k (FY, 2019) | Revenue (est.) $4.2b (FY, 2019) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $912k (FY, 2019) | Cost of goods $547.8m (FY, 2019) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit ($312k) (FY, 2019) | Gross profit $3.6b (FY, 2019) |
Net income | Net income ($290.2m) (FY, 2019) | Net income ($248.5m) (FY, 2019) | Net income ($276.2m) (FY, 2019) | Net income ($44.7m) (FY, 2019) | Net income $1.2b (FY, 2019) |
Operating ⚠ | |||||
Patents Issued | Patents Issued 240 (FY, 2016) | Patents Issued 2 (FY, 2016) | Patents Issued N/A | Patents Issued 88 (FY, 2016) | Patents Issued N/A |
Patents Pending | Patents Pending 280 (FY, 2016) | Patents Pending N/A | Patents Pending N/A | Patents Pending 115 (FY, 2016) | Patents Pending N/A |
Phase I Trials Products | Phase I Trials Products 2 (FY, 2016) | Phase I Trials Products N/A | Phase I Trials Products 1 (FY, 2018) | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products N/A |
Phase II Trials Products | Phase II Trials Products 4 (FY, 2016) | Phase II Trials Products N/A | Phase II Trials Products 2 (FY, 2018) | Phase II Trials Products 2 (FY, 2016) | Phase II Trials Products N/A |
Phase III Trials Products | Phase III Trials Products 1 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2018) | Phase III Trials Products 2 (FY, 2016) | Phase III Trials Products N/A |
Pre-Clinical Phase Products | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products N/A | Pre-Clinical Phase Products 3 (FY, 2018) | Pre-Clinical Phase Products 1 (FY, 2016) | Pre-Clinical Phase Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 468.9m | Total funding raised $ 145m | Total funding raised $ 98m | Total funding raised $ 153.4m | Total funding raised $ 2.4m |
For sources of this data, please see the company profile
View company profiles
Aimmune Therapeutics
HQ
Brisbane, US
Employees
275↑ 5% increase
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies.
View companyMyoKardia
HQ
South San Francisco, US
Employees
235↑ 42% increase
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
View companyOtonomy
HQ
San Diego, US
Employees
49
Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear.
View companyVertex Pharmaceuticals
HQ
Boston, US
Employees
3,000↑ 20% increase
Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
View company